SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant upward momentum and extreme volatility following a fresh development regarding a potential deal for Greenland, which led to the cancellation of previously scheduled tariffs. The community is actively discussing this "TACO trade" and the substantial gains for those who "bought the dip," while some express frustration over perceived market manipulation by political announcements. This event highlights the influential role of geopolitical and trade news in driving rapid market movements.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amidst extreme intraday volatility, largely driven by President Trump's shifting stance on Greenland and subsequent EU tariff developments. The community is actively debating the recurring 'Taco trade' phenomenon, where market swings tied to geopolitical headlines create rapid 'buy the dip' opportunities and significant losses for 'bears' in a highly reactive trading environment.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is currently trending after its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This news has ignited intense community discussion, with traders anticipating a potential short squeeze and substantial upside given the stock's low float and the expanded market access within the VA healthcare system. Many are celebrating significant gains and drawing comparisons to other recently volatile low-float plays.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is a top trending stock following a wave of analyst upgrades that significantly raised price targets and the company's revenue outlook. Despite experiencing considerable intraday volatility and perceived selling pressure from a recent equity offering, the community remains bullish, actively discussing buying the dip and anticipating future growth in the defense and autonomous systems sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to its new licensing agreement with Pfizer for the Matrix-M adjuvant, validating the platform's broad potential beyond COVID-19. The community is actively discussing the likelihood of a significant short squeeze, given the substantial short interest and growing interest from major pharmaceutical partners. Despite this positive development, many investors are urging management to implement further actions like share buybacks to fully capitalize on Matrix-M's value and counter persistent short pressure.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to recent service outages affecting its 365 suite and ongoing debate surrounding its AI strategy and investment in OpenAI, amplified by Elon Musk's lawsuit. While some investors see current price levels as an opportune moment to buy a fundamentally strong company, others point to broader mega-cap tech weakness and competitive pressures as key drivers of the decline ahead of its earnings report.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending amid high community discussion regarding its Anktiva immunotherapy, with optimism fueled by anticipated FDA advancements for bladder cancer and recent international regulatory wins. Investors are actively debating a potential short squeeze, given the substantial short interest and rising borrow costs, while also highlighting the company's ambitious goal to revolutionize cancer treatment. The broader context of global approvals and a strong product pipeline sustains a bullish outlook despite market volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is soaring as intensifying geopolitical tensions, particularly concerns over a potential US-EU trade conflict and declining trust in fiat currencies, drive strong safe-haven demand. Investors are keenly watching if this rally to unprecedented levels reflects gold's indispensable role amidst global instability, or if the market is nearing a 'blow-off top' fuelled by speculative 'fear narratives'.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing an explosive rally, driven by analyst upgrades and an unprecedented AI-driven memory and data storage demand, contributing to tight supply conditions across the sector. The community is fiercely divided, with enthusiastic bulls touting it as an "infinite money glitch" and the "next NVDA," while bears warn of a "scam" and "manipulated trash" poised for an epic crash. Its parabolic ascent, seemingly detached from broader market movements, fuels intense debate over its extreme valuation and whether its momentum can be sustained into upcoming earnings.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending after securing a position on the U.S. Missile Defense Agency's SHIELD contract, making it eligible for future "Golden Dome" defense AI task orders. This news is driving strong community optimism, as many anticipate substantial sovereign AI deals and view recent price movements as opportune buying points before an expected short squeeze and significant valuation breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Vanda (VNDA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

<ul class="summary-bullets"><li>Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research.</li><li>The company emphasized Tasimelteon’s well-established safety profile.&nbsp;</li><li>The company had recently received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting.</li></ul>Shares of Vanda Pharmaceuticals Inc. (VNDA) fell 10% in premarket trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) stated that its supplemental New Drug Application for HETLIOZ (tasimelteon) to treat jet lag disorder cannot be approved in its current form.While the FDA acknowledged positive results from Vanda’s clinical trials, it cited concerns that the controlled phase-advance protocols used in the studies do not fully replicate real-world jet travel conditions, including reduced oxygen pressure, noise, and lighting changes.Vanda said it disagrees with the FDA assessment, noting that phase-advance models are widely accepted in circadian rhythm research and effectively simulate core jet-lag symptoms. The company emphasized tasimelteon’s well-established safety profile and demonstrated benefits on sleep and next-day alertness.This comes after the company received FDA approval for NEREUS (Tradipitant), a motion-sickness treatment aimed at preventing vomiting on December 31, 2025.The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years. Vanda expects to launch NEREUS in the coming months. Beyond motion sickness, Vanda is advancing tradipitant in clinical development for other conditions driven by similar pathways, including gastroparesis and nausea linked to GLP-1 therapies.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned 'bullish' from 'neutral' a day earlier.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/VNDA_jpg_66bd88803d.webp" alt="VNDA.jpg" width="922" height="88"><figcaption>&nbsp;</figcaption></figure>One bullish user sees strong buy at this level, stating that the motion sickness drug approval is a much bigger news than today's update.<stembedurl>https://stocktwits.com/pablo4/message/641232419</stembedurl>Over the past one year, <a href="https://stocktwits.com/symbol/VNDA">VNDA shares</a> have gained around 52%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game, on September 05, 2025, at Comerica Park in Detroit, Michigan. 

Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application

The FDA cited concerns that the controlled phase advance protocols used in studies do not fully replicate real-world jet travel conditions.

Equity

Q1 EPS Estimate for Vanda Pharmaceuticals Raised by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in...

FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.read more...

Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen upgraded Vanda Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...

What's Going On With Vanda Pharmaceuticals Stock Wednesday?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion.read more...

Vanda Pharmaceuticals Stock Surges 29% After FDA Clears Motion Sickness Drug

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) shares jumped 29.13%, trading at $9.08, up $2.05, after the company announced that the U.S. Food and Drug Administration approved NEREUS (tradipitant...

Vanda Pharmaceuticals (NASDAQ:VNDA) Hits New 52-Week High - Here's What Happened

Vanda Pharmaceuticals (NASDAQ:VNDA) Reaches New 12-Month High - Still a Buy...

Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 12,270 call options on the stock. This represents an...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VNDA News

VNDAVanda Pharmaceuticals Inc